PPT-Targeting KRAS G12C in Solid Tumors
Author : morton | Published Date : 2022-06-01
A New Anticancer Approach Marwan Fakih MD Professor Section Head Gastrointestinal Oncology Medical Oncology City of Hope Comprehensive Cancer Center Duarte
Presentation Embed Code
Download Presentation
Download Presentation The PPT/PDF document "Targeting KRAS G12C in Solid Tumors" is the property of its rightful owner. Permission is granted to download and print the materials on this website for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Targeting KRAS G12C in Solid Tumors: Transcript
A New Anticancer Approach Marwan Fakih MD Professor Section Head Gastrointestinal Oncology Medical Oncology City of Hope Comprehensive Cancer Center Duarte California Supported by an educational grant from Amgen. Beena Brahmbhatt Department of Pathology Gujarat Cancer and Research Institute NCH Campus Asarwa Ahmedabad INDIA E Mail ID beenashamikyahoocom KEY WORDS bone marrow metastasis solid tumors trephine biopsy GUJARAT MEDICAL JOURNAL AUGUST2014 Vol 69 pathways. Federico Cappuzzo. Istituto Toscano Tumori. Ospedale Civile. Livorno-. Italy. Istituto Toscano Tumori – Livorno, Italy. Molecular events in lung cancer. Adenocarcinoma. Unknown. 53.8%. KRAS. Ranee Mehra, MD. Fox Chase Cancer Center. Philadelphia, PA. Disclosures. Consulting – Novartis, Bristol Myers Squib. Spouse is employee of GSK. Acknowledgment: J. Weiss. Ras-Raf-MEK-ERK1/2 MAP . kinase. Does . the New EPOC trial . eliminate. . Anti. -EGFR antibodies as part of pre-op therapy for curable . liver-only . mCRC. ? . YES!. Cathy Eng, M.D., F.A.C.P.. Associate Professor. Associate Medical Director, Colorectal Center. Pseudopapillary. Epithelial Tumor (SPEN) – Imaging features.. Dr. . Ayshath. . Shamseena. 2. nd. Yr Post Graduate . Dept. Of Radio Diagnosis. Yenepoya. Medical College . Mangalore, Karnataka.. YENEPOYA. Quale chemioterapia sistemica?. Dott. Giuseppe Colosini. U.O. Oncologia Ospedale Manerbio. Az. Ospedaliera Desenzano D/G. L’innovazione nell’organizzazione e nell’assistenza in Chirurgia-. 3° Convegno congiunto della società lombarda triveneta di chiururgia. DR HEYAM AWAD. FOLLICULAR AND LUTEAL CYSTS.. POLYCYSTIC OVARY.. OVARIAN TUMORS.. FOLLICULAR AND LUTEAL CYSTS. COMMON.. CONSIDERED VARIANTS OF NORMAL PHYSIOLOGY.. ORIGENATE FROM UNRUPTURED FOLLICLES.. Begin . Dermoid. cyst. Mucocele. Hemangioma. Lymphangioma. Malignant . rabdomyosarcoma. Benign tumors of the orbit . can develop from infancy and grow rapidly or slowly. It can be superficial and easily identifiable by external presentation, palpation and x – rays or CT scan . Committee on Ways & Means. Background. May 14, 2013: TIGTA Audit Report, “Inappropriate Criteria Were Used to Identify Tax-Exempt Applications for Review”. Detailed IRS targeting of certain groups based on political beliefs. Begin . Dermoid. cyst. Mucocele. Hemangioma. Lymphangioma. Malignant . rabdomyosarcoma. Benign tumors of the orbit . can develop from infancy and grow rapidly or slowly. It can be superficial and easily identifiable by external presentation, palpation and x – rays or CT scan . Assistant Prof . Fadia. Al-. Izzi. Benign ovarian cysts are common, frequently asymptomatic . &. often resolve spontaneously. .. 90%of all ovarian tumors are benign . although . this varies with age.. 639 : 639-646(2006) 0.0001), and between those with solid-and non-solid-model in patients with curative resection revealed that age,tumor diameter, depth of invasion, lymphnode metastasisdifferentiate S.K.Medical. College, . Muz. Ovarian tumors. 80% are . benign. . occuring. mostly in young women between the ages of 20 and 45 years. Borderline . tumors. . occur at slightly older ages. Malignant . Harriet Feilotter, PhD, FCCMG, FACMG. Professor, Dept of Pathology and Molecular Medicine, Queen’s U. Director, Molecular Genetics, KHSC. 2. Disclosures. I have the following financial relationships to disclose: .
Download Document
Here is the link to download the presentation.
"Targeting KRAS G12C in Solid Tumors"The content belongs to its owner. You may download and print it for personal use, without modification, and keep all copyright notices. By downloading, you agree to these terms.
Related Documents